Table of Contents Author Guidelines Submit a Manuscript
Current Gerontology and Geriatrics Research
Volume 2017, Article ID 4276047, 5 pages
https://doi.org/10.1155/2017/4276047
Research Article

Diseases Linked to Polypharmacy in Elderly Patients

2nd Department of Internal Medicine, General and Oncological Hospital of Kifissia “Agioi Anargyroi”, Noufaron and Timiou Stavrou 14, Athens, Greece

Correspondence should be addressed to Ioannis Vrettos; rg.oohay@isotterv

Received 27 October 2017; Accepted 7 December 2017; Published 25 December 2017

Academic Editor: Tomasz Kostka

Copyright © 2017 Ioannis Vrettos et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. V. Fano, F. Chini, P. Pezzotti, and K. Bontempi, “Estimating the prevalence and the determinants of polypharmacy using data from a health administrative database: a comparison of results obtained employing different algorithms,” Advances in Pharmacoepidemiology and Drug Safety, vol. 3, article 151, 2014. View at Google Scholar
  2. T. Linjakumpu, S. Hartikainen, T. Klaukka, J. Veijola, S.-L. Kivelä, and R. Isoaho, “Use of medications and polypharmacy are increasing among the elderly,” Journal of Clinical Epidemiology, vol. 55, no. 8, pp. 809–817, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. H. F. Thomas, P. M. Sweetnam, B. Janchawee, and D. K. Luscombe, “Polypharmacy among older men in South Wales,” European Journal of Clinical Pharmacology, vol. 55, no. 5, pp. 411–415, 1999. View at Publisher · View at Google Scholar · View at Scopus
  4. L. Bjerrum, J. Søgaard, J. Hallas, and J. Kragstrup, “Polypharmacy: correlations with sex, age and drug regimen,” European Journal of Clinical Pharmacology, vol. 54, no. 3, pp. 197–202, 1998. View at Publisher · View at Google Scholar · View at Scopus
  5. P. M. Mannucci, A. Nobili, and REPOSI Investigators, “Multimorbidity and polypharmacy in the elderly: lessons from REPOSI,” Internal and Emergency Medicine, vol. 9, no. 7, pp. 723–734, 2014. View at Publisher · View at Google Scholar
  6. D. A. Gorard, “Escalating polypharmacy,” QJM: An International Journal of Medicine, vol. 99, no. 11, pp. 797–800, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. R. A. Deyo, D. C. Cherkin, and M. A. Ciol, “Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases,” Journal of Clinical Epidemiology, vol. 45, no. 6, pp. 613–619, 1992. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Katz, “Assessing self-maintenance: activities of daily living, mobility, and instrumental activities of daily living,” Journal of the American Geriatrics Society, vol. 31, no. 12, pp. 721–727, 1983. View at Publisher · View at Google Scholar · View at Scopus
  9. S. C. Appleton, G. A. Abel, and R. A. Payne, “Cardiovascular polypharmacy is not associated with unplanned hospitalisation: evidence from a retrospective cohort study,” BMC Family Practice, vol. 15, no. 1, article 58, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. V. Mastromarino, M. Casenghi, M. Testa et al., “Polypharmacy in heart failure patients,” Current Heart Failure Reports, vol. 11, no. 2, pp. 212–219, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Y. Wong, S. I. Chaudhry, M. M. Desai, and H. M. Krumholz, “Trends in comorbidity, disability, and polypharmacy in heart failure,” American Journal of Medicine, vol. 124, no. 2, pp. 136–143, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. S. B. Salih, M. Yousuf, H. Durihim, H. Almodaimegh, and H. Tamim, “Prevalence and associated factors of polypharmacy among adult Saudi medical outpatients at a tertiary care center,” Journal of Family and Community Medicine, vol. 20, no. 3, pp. 162–167, 2013. View at Publisher · View at Google Scholar
  13. L. J. G. Veehof, R. E. Stewart, F. M. Haaijer-Ruskamp, and B. Meyboom-de Jong, “The development of polypharmacy. A longitudinal study,” Journal of Family Practice, vol. 17, no. 3, pp. 261–267, 2000. View at Publisher · View at Google Scholar · View at Scopus
  14. U. Junius-Walker, G. Theile, and E. Hummers-Pradier, “Prevalence and predictors of polypharmacy among older primary care patients in Germany,” Journal of Family Practice, vol. 24, no. 1, pp. 14–19, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. J. George, P. Devi, D. Y. Kamath, N. Anthony, N. S. Kunnoor, and S. S. Sanil, “Patterns and determinants of cardiovascular drug utilization in coronary care unit patients of a tertiary care hospital,” Journal of Cardiovascular Disease Research, vol. 4, no. 4, pp. 214–221, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Proietti, V. Raparelli, B. Olshansky, and G. Y. H. Lip, “Polypharmacy and major adverse events in atrial fibrillation: observations from the AFFIRM trial,” Clinical Research in Cardiology, vol. 105, no. 5, pp. 412–420, 2016. View at Publisher · View at Google Scholar · View at Scopus
  17. D. R. Bueno, H. L. Monteiro, C. S. C. Rosa, J. S. Codogno, R. A. Fernandes, and M. F. N. Marucci, “Association between physical activity levels and polypharmacy in hypertensive patients,” Medicina (Brazil), vol. 49, no. 3, pp. 240–247, 2016. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Dutta and L. Prashad, “Prevalence and risk factors of polypharmacy among elderly in India: Evidence from SAGE data,” International Journal of Public Mental Health and Neurosciences, vol. 2, no. 2, pp. 11–16, 2015. View at Google Scholar
  19. C. B. Good, “Polypharmacy in elderly patients with diabetes,” Diabetes Spectrum, vol. 15, no. 4, pp. 240–248, 2002. View at Publisher · View at Google Scholar
  20. S. Bauer and M. A. Nauck, “Polypharmacy in people with Type 1 and Type 2 diabetes is justified by current guidelines-a comprehensive assessment of drug prescriptions in patients needing inpatient treatment for diabetes-associated problems,” Diabetic Medicine, vol. 31, no. 9, pp. 1078–1085, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Díez-Manglano, J. Barquero-Romero, P. A. Mena et al., “Polypharmacy in patients hospitalised for acute exacerbation of COPD,” European Respiratory Journal, vol. 44, no. 3, pp. 791–794, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. F. M. Franssen, M. A. Spruit, and E. F. M. Wouters, “Determinants of polypharmacy and compliance with GOLD guidelines in patients with chronic obstructive pulmonary disease,” International Journal of Chronic Obstructive Pulmonary Disease, vol. 6, no. 1, pp. 493–501, 2011. View at Google Scholar · View at Scopus
  23. F. Clague, S. W. Mercer, G. McLean, E. Reynish, and B. Guthrie, “Comorbidity and polypharmacy in people with dementia: insights from a large, population-based cross-sectional analysis of primary care data,” Age and Ageing, vol. 46, no. 1, pp. 33–39, 2017. View at Google Scholar
  24. H.-Y. Park, J.-W. Park, H. J. Song, H. S. Sohn, and J.-W. Kwon, “The association between polypharmacy and dementia: a nested case-control study based on a 12-year longitudinal cohort database in South Korea,” PLoS ONE, vol. 12, no. 1, Article ID 0169463, 2017. View at Publisher · View at Google Scholar · View at Scopus
  25. S. L. Slabaugh, V. Maio, M. Templin, and S. Abouzaid, “Prevalence and risk of polypharmacy among the elderly in an outpatient setting: A retrospective cohort study in the Emilia-Romagna Region, Italy,” Drugs & Aging, vol. 27, no. 12, pp. 1019–1028, 2010. View at Publisher · View at Google Scholar · View at Scopus